Data from migration kinetics studies can be used to develop models that predict levels of leachables and extractables at different temperatures and time points.
Image Courtesy Of PPD Laboratories.
A controlled extraction study early in the pharmaceutical development process can provide an understanding of potential leachables from appropriate drug product container/closure system components, manufacturing process components, and/or product administration components.
While a controlled-extraction study provides the worst-case possible leachables and amounts, it cannot fully predict the presence of specific leachables and their amounts. A simulation or forced migration study is commonly used to predict more realistic leachables profile and amounts.
A fundamental question for any simulation or forced migration study is what the optimum temperature and duration should be in order to predict the amount of leachables that would be released by the end of the product’s shelf life, or at other specific points.
The authors designed a forced migration study to address that question and determine how the amount of leachables would change with intended temperature changes at multiple time points required for drug product stability studies and at the end of the drug’s shelf life.
The research also explored whether the level of leachables could be predicted using data that had been generated at previous time points.
Download the article as a PDF.Benton Cartledge is associate research scientist; Jason Carmichael is assistant scientist; Nathan Haag is a scientist; Eric Hansen is a scientist; Travis Lato is an assistant scientist; Xiaochun Yu is a senior principal scientist; all with PPD Laboratories, 8551 Research Way, Suite 90, Middleton, WI 53562.
BioPharm International
Vol. 33, No. 8
August 2020
Pages: 40-44
When referring to this article, please cite it as B. Cartledge, et al., “Predicting Extractables and Leachables from Container Stoppers,” BioPharm International33 (8) 2020.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.